Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on gastrointestinal (GI) and rare diseases, and its news flow reflects this specialization. Investors and followers of IRWD news will see regular updates on the performance and clinical development of its key assets, particularly LINZESS® (linaclotide) and apraglutide.
News about LINZESS often covers U.S. net sales, prescription demand trends based on IQVIA data, and changes in financial guidance related to collaboration revenue and adjusted EBITDA. Ironwood and its U.S. partner AbbVie share equally in U.S. brand collaboration profits, so quarterly and full-year results frequently highlight LINZESS commercial margin, net profit for the U.S. brand collaboration, and the impact of pricing dynamics, gross-to-net rebate reserves and healthcare policy changes.
For apraglutide, Ironwood’s news includes clinical and regulatory milestones in short bowel syndrome with intestinal failure (SBS-IF). Press releases describe data from the STARS Phase 3 trial and the STARS Extend long-term extension study, including the number of apraglutide-dosed patients achieving enteral autonomy, as well as feedback from the U.S. Food and Drug Administration on the need for a confirmatory Phase 3 trial. Updates on the timing and design of this confirmatory trial and on regulatory submissions are recurring themes.
IRWD news also covers financial guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA, along with restructuring activities, cost management efforts and strategic reorganization steps. Additional announcements address topics such as Nasdaq listing notifications, changes in the company’s independent registered public accounting firm, participation in investor and scientific conferences, and the ongoing review of strategic alternatives with financial advisors.
By following this IRWD news page, readers can track how Ironwood’s GI and rare disease programs progress over time, how financial expectations evolve, and how regulatory, commercial and strategic developments may influence the company’s outlook.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported a strong financial performance for 2021, with total revenues reaching $414 million, driven largely by $400 million from U.S. LINZESS collaboration revenue. The company reported a GAAP net income of $528 million, boosted by a non-recurring tax benefit. Ironwood also made strategic advancements in its pipeline, initiating clinical studies for IW-3300 and CNP-104, targeting unmet medical needs in visceral pain and primary biliary cholangitis (PBC). The company ended 2021 with $620 million in cash and equivalents, positioning itself favorably for growth in 2022.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced strong financial guidance, projecting LINZESS to exceed
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.
Ironwood Pharmaceuticals announced the appointment of Sravan K. Emany as the new Chief Financial Officer effective December 6, 2021. Emany, who has extensive experience in financial strategy within the healthcare sector, will oversee all financial operations and report to CEO Thomas McCourt. McCourt expressed confidence that Emany's expertise will enhance Ironwood's impact on gastrointestinal (GI) healthcare and benefit shareholders. Previously, Emany held leadership roles at Integra LifeSciences and has 18 years in investment banking.
Ironwood Pharmaceuticals reported a strong third quarter in 2021, with GAAP net income of $55.8 million and adjusted EBITDA of $65.5 million. LINZESS prescription demand surged 12% year-over-year, driving U.S. net sales to $253 million, up 5% from the previous year. Ironwood ended the quarter with $574 million in cash. The company expanded its pipeline by entering into an option agreement with COUR Pharmaceuticals for CNP-104, targeting primary biliary cholangitis, a rare autoimmune disease. The firm anticipates 6% to 8% growth in LINZESS net sales for 2021.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced a collaboration with COUR Pharmaceutical for the investigational therapy CNP-104, aimed at treating Primary Biliary Cholangitis (PBC), a rare autoimmune disease affecting 133,000 people in the U.S. Ironwood will pay approximately
Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2021 investor update conference call on November 4, 2021, at 8:30 a.m. ET. Interested participants can join via phone or webcast through the company's website. The call will be replayable starting November 4 at 11:30 a.m. ET until November 18, 2021. Ironwood is a leader in gastrointestinal healthcare, known for its innovation in treating GI diseases, specifically with its LINZESS® product for IBS-C and CIC. Founded in 1998, it is based in Boston, Massachusetts.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will participate in two upcoming virtual investor conferences in September 2021. The Wells Fargo Healthcare Conference is scheduled for September 10 at 2:00 p.m. ET, and the Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 13 at 2:45 p.m. ET. Investors can access live webcasts on Ironwood's website, with replays available for 14 days post-conference. Ironwood focuses on developing medicines for gastrointestinal diseases, notably linaclotide for IBS-C and CIC.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
